Product logins

Find logins to all Clarivate products below.


Ekaterina Kotelnikova

Associate Director for Discovery and Translational Science Consulting

Ekaterina is a highly experienced professional in bioinformatics consulting, with over 20 years of expertise in bioinformatics and systems biology. She holds a Ph.D. in molecular evolution and has a background in biophysics. Throughout her career, Ekaterina has led teams in both academic and commercial settings, specializing in drug discovery, patient subpopulation selection, and precision medicine applications using multi-omics approaches, network, and pathway analysis. She has been actively involved in establishing partnerships with interdisciplinary teams and has made significant contributions to grant applications and deliveries.

Driven by her passion for translational medicine, Ekaterina co-founded a company dedicated to NGS-based cancer treatment predictions. Working closely with molecular oncologists, bioinformaticians, and systems biologists, the company focused on the application of systems biology to precision medicine, benefiting from seed investments and grants.

Ekaterina plays a crucial role in client-facing activities and business development, conducting client needs assessments, exploring market opportunities, proposing innovative solutions, and successfully overseeing project management across various therapy areas, including oncology, neuromuscular, skin, rare, and autoimmune diseases.

Latest news

News November 6, 2025
Fujifilm Selects IPfolio from Clarivate

Maximizing the value of intellectual property assets to support business growth London, U.K. November 6, 2025. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that…

News October 30, 2025
Clarivate Pulse of the Library Report Reveals Link Between AI Literacy, AI Implementation and Confidence

Drawing on insights from over 2,000 librarians representing academic, national and public libraries globally, the report offers an up-to-date view of how they are adapting to rapid change London, U.K.,…

News October 29, 2025
Clarivate Reports Third Quarter 2025 Results

— Continued acceleration of organic ACV — — Raises 2025 Revenues Outlook — — Repurchased 11.7 million ordinary shares and repaid $100 million of debt in the third quarter—  …

Related resources

Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center
The trends to watch in 2025 The trends to watch in 2025
Blog January 8, 2025
The trends to watch in 2025